Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia Purchases Rights To Distribute MSI Software In Asia-Pacific

Premium

PRINCETON, NJ--Pharmacopeia has bought the right to distribute Molecular Simulations software in Japan and other Asia Pacific countries. The $10 million deal was with Teijin, a Japanese chemical and pharmaceutical company. Teijin Molecular Simulations, owned jointly by Molecular Simulations and Teijin, was established in 1992. In 1998, Molecular Simulations became a wholly owned subsidiary of Pharmacopeia.

Joseph Mollica, chairman and CEO of Pharmacopeia, said the agreement will give his company "full control over our distribution strategy in Asia, a market that accounted for 20 percent of our total Molecular Simulations software sales in 1998."

Ryoka Systems, a subsidiary of Mitsubishi Chemical, has been appointed exclusive distributor of Molecular Simulations software in Japan.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.